Outcomes of corticosteroid treatment in critically ill COVID-19 patients
Article Sidebar
Main Article Content
Abstract
Objective: This study aims to examine the impact of low-dose and high-dose corticosteroids on the clinical outcomes and mortality of critically ill patients with COVID-19 in intensive care units.
Material and Methods: This study was conducted on 197 confirmed COVID-19 patients who received corticosteroid therapy in the intensive care unit (ICU) between June 1st and December 31st, 2020. Patients were divided into two groups for low- and high-dose corticosteroid therapy. Both groups were compared according to demographic features, comorbid conditions, laboratory parameters, as well as the ordinal scale for clinical improvement (OSCI), hospital mortality, and length of stay in the intensive care unit.
Results: A total of 140 patients received low-dose corticosteroids, while 57 patients received high-dose corticosteroid therapy. Our findings revealed a significantly higher median length of stay in the ICU and mortality in the group that received high-dose corticosteroid therapy. We observed a significant reduction in ferritin and D-dimer levels in the group receiving high-dose corticosteroid therapy (p < 0.003, p < 0.012, respectively). Furthermore, OSCIs on admission, day 5, and day 10 after corticosteroid therapy were higher in the group receiving high-dose corticosteroids.
Conclusion: The results of this study indicate that high-dose corticosteroid therapy in critically ill patients with COVID-19 is associated with high mortality rates and prolonged intensive care stays.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-04-27
Published 2024-04-29
References
S Musa. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now? Arab J Gastroenterol 2020; 21: 3–8.
Wang W, Tang J, Wei F. Up dated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol 2020; 92: 441–447.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–1720.
Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: immunology and treatment options. Clin Immunol. 2020;215:108448
Cao B, Wang Y, Wen D, et al. Atrial of lopinavir-ritonavir in adults hospitalized with severe covid-19.N Engl J Med 2020;382:1787e99.
Yeming Wang DZ, Du G, Du R, et al. Remdesivir in adults with severe covid-19: results of a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2020;395:1569e78i.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033–1034.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Chen RC, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441–1452.
Sung JJ, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004;59(5):414–420.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8):693–704. https://doi.org/10.1056/NEJMoa2021436.
Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial BMC Infectious Diseases (2021) 21:337.
Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. EurRespir J 2020; 56: 2002808https://doi.org/10.1183/13993003.02808-2020.
Batirel A, Demirhan R, Eser N, et al. Pulse Steroid Treatment for Hospitalized Adults with COVID-19 Turk J MedSci. 2021 Apr 21. doi: 10.3906/sag-2101-243.
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of 6 Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: TheCoDEX Randomized Clinical Trial. JAMA 2020; 324: 1307-1316. doi: 10.1001/jama.2020.17021.
World Health Organization. WHO R&D Blueprint-Novel Coronavirus COVID-19.Therapeutic Trial Synopsis.2020. Available from: https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis.Accessed13 January 2021.
Chandini RM, Abrar AC, Michelle B, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09.BMC Infectious Diseases (2018) 18:637https://doi.org/10.1186/s12879-018-3548-0
Sung JJY, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59: 414–420.
Lee N, Allen KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J ClinVirol 2004; 31: 304–309.
Lee DT, Wing YK, Leung HC, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 2004; 39: 1247–1249.
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. https://doi.org/10.1056/NEJMoa2021436.
Ruiz-Irastorza G, Pijoan JI, Bereciartua E, et al. Cruces COVID Study Group. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. PLoSOne. 2020 Sep 22; 15(9):e0239401. https://doi.org/10.1371/journal.pone.0239401 PMID: 32960899.
Lo´pez Zu´ñiga MA´, Moreno-Moral A, Ocaña-Granados A, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. PLoS ONE 16(1): e0243964.https://doi.org/10.1371/journal. pone.0243964
Liu F, Ji C, LuoJ, et al. Clinical characteristics and corticosteroids application of different clinical types in patients with coronavirusdisease 2019. SciRep. 2020; 10(1):13689. Published 2020 Aug 13. https://doi.org/10.1038/s41598-020-70387-2 PMID: 32792492
Patricia MS, Mayte BA, Arianna Sibila PB, et al. Methylprednisolone pulse therapy: An alternative management of severe COVID-19 Respir Med Case Rep. 2020 Sep 12;31:101221. doi: 10.1016/j.rmcr.2020.101221. eCollection 2020.
Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003; 9:1381– 1387.
Kenneth PS, Leonard DH, Richard BG, et al. Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome, N Engl J Med. 2006 Apr 20;354(16):1671-84. doi: 10.1056/NEJMoa051693.
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderateor Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020; 324: 1307-1316. doi: 10.1001/jama.2020.17021
Bernard GR, Luce JM, Sprung CL, et al. High-dosecorticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1565-70.
Weigelt JA, Norcross JF, Borman KR, et al. Early steroid therapy for respiratory failure. Arch Surg 1985;120: 536-40.
Li XW, Jiang RM, Guo JZ. Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report. Chin J InternMed 2003; 42:378 –381
Aikaterini P, Jeanwoo Y, Prabhjot G, et al. High-dose methylprednisolone in non intubated patients with severe COVID-19 pneumonia . Eur J ClinInvest. 2020;00:e13458. https://doi.org/10.1111/eci.13458